Alnylam Pharma (ALNY) Tops Q3 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
Alnylam Pharmaceuticals Reports Third Quarter 2020 Financial Results and Highlights Recent Period Activity
November 5, 2020 8:00 AM ESTAchieved Third Quarter 2020 ONPATTRO® Global Net Product Revenue of $82.5 Million, Including Over 20% Quarterly U.S. Growth, with More Than 1,150 Patients on Commercial Product Worldwide
Achieved Third Quarter 2020 GIVLAARI® Global Net Product Revenue of $16.7 Million, with More Than 150 Patients on Commercial Product Worldwide
Received Positive Opinions for OXLUMO (lumasiran) and LEQVIO® (inclisiran) from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), Positioning the Company for Potentially Four Approved RNAi Therapeutic Medicines by Year-End 2020
Increased 2020 Guidance Range for ONPATTRO Revenue from $280-$300 Million... More
